BOLD-100
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].
Product Specifications
CAS Number
197723-00-5
Product Name Alternative
NKP-1339; IT-139; KP-1339
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bold-100.html
Concentration
10mM
Purity
95.20
Solubility
DMSO : ≥ 59 mg/mL
Smiles
[Cl-][Ru+3]([Cl-])([Cl-])([N]1=CC2=C(N1)C=CC=C2)([N]3=CC4=C(N3)C=CC=C4)[Cl-].[Na+]
Molecular Formula
C14H12Cl4N4NaRu
Molecular Weight
502.14
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PIK3C2B (Phosphatidylinositol-4-phosphate 3-kinase C2 Domain-containing Subunit beta, PI3K-C2-beta, Phosphoinositide 3-kinase-C2-beta, PIK3C2B, PtdIns-3-kinase C2 Subunit beta, C2-PI3K, DKFZp686G16234) (AP)
PIK3C2B (Phosphatidylinositol-4-phosphate 3-kinase C2 Domain-containing Subunit beta, PI3K-C2-beta, Phosphoinositide 3-kinase-C2-beta, PIK3C2B, PtdIns-3-kinase C2 Subunit beta, C2-PI3K, DKFZp686G16234) (AP)
